[go: up one dir, main page]

EA200001164A1 - КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА - Google Patents

КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА

Info

Publication number
EA200001164A1
EA200001164A1 EA200001164A EA200001164A EA200001164A1 EA 200001164 A1 EA200001164 A1 EA 200001164A1 EA 200001164 A EA200001164 A EA 200001164A EA 200001164 A EA200001164 A EA 200001164A EA 200001164 A1 EA200001164 A1 EA 200001164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
hmg
pharnesiltransferase
koa
reductases
Prior art date
Application number
EA200001164A
Other languages
English (en)
Other versions
EA003860B1 (ru
Inventor
Джюдит Лиопольд
Роджер Шофильд Ньютон
Original Assignee
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани
Publication of EA200001164A1 publication Critical patent/EA200001164A1/ru
Publication of EA003860B1 publication Critical patent/EA003860B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Описаны новые комбинации ингибиторов энзимов протеин фарнезилтрансферазы и HMG КоА редуктазы, а также способы приготовления и фармацевтические композиции из них, которые применяют при предупреждении или лечении рака, рестеноза, псориаза, эндометриоза, атеросклероза или вирусных инфекций.Отчет о международном поиске был опубликован 2000.01.06.
EA200001164A 1998-05-12 1999-05-10 КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА EA003860B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8520298P 1998-05-12 1998-05-12
US9225398P 1998-07-10 1998-07-10
PCT/US1999/010188 WO1999058505A2 (en) 1998-05-12 1999-05-10 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer

Publications (2)

Publication Number Publication Date
EA200001164A1 true EA200001164A1 (ru) 2001-06-25
EA003860B1 EA003860B1 (ru) 2003-10-30

Family

ID=26772425

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001164A EA003860B1 (ru) 1998-05-12 1999-05-10 КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА

Country Status (25)

Country Link
US (1) US6492410B1 (ru)
EP (1) EP1077949A2 (ru)
JP (1) JP2002514628A (ru)
KR (1) KR20010043529A (ru)
CN (1) CN1171874C (ru)
AP (1) AP2000001984A0 (ru)
AU (1) AU758891B2 (ru)
BG (1) BG105003A (ru)
BR (1) BR9911785A (ru)
CA (1) CA2331295A1 (ru)
EA (1) EA003860B1 (ru)
EE (1) EE200000660A (ru)
GE (1) GEP20032996B (ru)
HR (1) HRP20000771A2 (ru)
HU (1) HUP0102322A3 (ru)
ID (1) ID27933A (ru)
IL (1) IL139502A0 (ru)
IS (1) IS5713A (ru)
NO (1) NO20005680L (ru)
NZ (1) NZ508357A (ru)
OA (1) OA11551A (ru)
PL (1) PL344662A1 (ru)
SK (1) SK16742000A3 (ru)
WO (1) WO1999058505A2 (ru)
YU (1) YU68900A (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536405A (ja) * 1999-02-11 2002-10-29 イーデンランド、インコーポレイテッド ウイルス感染症の治療方法
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2005042710A1 (en) * 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
KR100930365B1 (ko) * 2006-11-09 2009-12-08 덕성여자대학교 산학협력단 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
NL9002031A (nl) 1990-09-14 1992-04-01 Voskuilen Woudenberg Bv Inrichting voor het bewerken van een uitwendig buisoppervlak.
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
DE69630120T2 (de) 1995-06-22 2004-04-08 Biogen, Inc., Cambridge Kristalle von fragmenten von cd40-liganden und deren verwendung
KR19990028303A (ko) * 1995-06-22 1999-04-15 한센 핀 베네드, 안네 제헤르 성장호르몬 방출 특성을 가지는 화합물
UA57081C2 (ru) 1997-06-16 2003-06-16 Пфайзер Продактс Інк. ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В СОЧЕТАНИИ С ИНГИБИТОРАМИ HMG CoA РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА

Also Published As

Publication number Publication date
EP1077949A2 (en) 2001-02-28
AU3979299A (en) 1999-11-29
HRP20000771A2 (en) 2001-06-30
CA2331295A1 (en) 1999-11-18
CN1171874C (zh) 2004-10-20
HUP0102322A2 (hu) 2001-11-28
WO1999058505A2 (en) 1999-11-18
AP2000001984A0 (en) 2000-12-31
JP2002514628A (ja) 2002-05-21
NZ508357A (en) 2002-09-27
WO1999058505A3 (en) 2000-01-06
YU68900A (sh) 2002-12-10
EE200000660A (et) 2002-04-15
BR9911785A (pt) 2001-04-03
NO20005680L (no) 2001-01-10
PL344662A1 (en) 2001-11-19
BG105003A (en) 2001-07-31
IL139502A0 (en) 2001-11-25
HUP0102322A3 (en) 2001-12-28
EA003860B1 (ru) 2003-10-30
AU758891B2 (en) 2003-04-03
KR20010043529A (ko) 2001-05-25
GEP20032996B (en) 2003-06-25
OA11551A (en) 2004-05-24
HK1038355A1 (en) 2002-03-15
CN1306515A (zh) 2001-08-01
US6492410B1 (en) 2002-12-10
SK16742000A3 (sk) 2001-07-10
NO20005680D0 (no) 2000-11-10
ID27933A (id) 2001-05-03
IS5713A (is) 2000-11-10

Similar Documents

Publication Publication Date Title
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
DK0767800T3 (da) Histidin- og homohistidinderivater som inhibitorer af protein farnesyltransferase
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
EA200200262A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE310011T1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
EA199800772A1 (ru) Производные 6-фенилпиридил-2-амина
EA199900021A1 (ru) Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
ID23877A (id) Senyawa-senyawa dan metode-metode untuk penghambatan ekspresi vcam-1
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199901031A1 (ru) Производные бензимидазола
UA39166C2 (ru) Производные n-гидроксимочевины, которые являются ингибиторами липоксигеназы у млекопитающих, способ их получения и способ ингибирования липоксигеназы у млекопитающих
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200001164A1 (ru) КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА
EA200000240A1 (ru) Соединения, препятствующие эффекту раннего превращения лекарственных средств
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
ATE255594T1 (de) Hepatitis b inhibitoren
EA200300388A1 (ru) 1-аминоалкилциклогексаны в качестве трипаноцидных агентов
LV12375A (lv) 1-(3-aminoindazol-5-il)-fenilmetil)-cikliskas urinvielas piemerotas ka HIV proteazes inhibitori
RU95106624A (ru) Гидроксиэтиламиносульфонамиды, промежуточные соединения, фармацевтическая композиция, способ ингибирования ретровирусных протеаз, способ лечения ретровирусных инфекций, способ лечения спида

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU